Tyrosine kinase inhibitors: the first decade

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) treatment transformed with imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), introduced in 1998.
• Imatinib targets the leukemogenic Bcr-Abl1 protein kinase, inducing sustained remissions and prolonged survival in CML patients.
• Resistance to imatinib and intolerance due to toxicity necessitate the development of alternative therapies.

Purpose of the Study:

• To review the progress in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) over the past decade.
• To discuss the development of novel TKIs aimed at overcoming resistance mechanisms, particularly Bcr-Abl1 kinase domain mutations.

Main Methods:

• Review of scientific literature and clinical trial data on TKI therapy for CML.
• Analysis of treatment outcomes, resistance mechanisms, and emerging therapeutic strategies.

Main Results:

• Second-generation TKIs, nilotinib and dasatinib, are approved for CML patients failing or intolerant to imatinib.
• Despite their efficacy, these agents can be ineffective due to highly resistant mutations, such as T315I.
• Novel agents targeting resistant mutations are under investigation in ongoing clinical trials.

Conclusions:

• TKI therapy has significantly advanced CML management, offering improved survival rates.
• Addressing resistance, especially the T315I mutation, remains a critical challenge in CML treatment.
• Ongoing research into novel TKIs holds promise for overcoming current therapeutic limitations in CML.